Strides Pharma Science Limited (NSE:STAR)
India · Delayed Price · Currency is INR 984.00
-9.00 (-0.91%)
Aug 21, 2026, 3:29 PM IST
Strides Pharma Science Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 90,901 | 86,435 | 61,675 | 72,114 | 25,858 | 31,121 | |
Market Cap Growth | 12.44% | 40.14% | -14.47% | 178.88% | -16.91% | -58.92% |
Enterprise Value | 106,853 | 103,068 | 81,726 | 96,197 | 55,452 | 54,820 |
Last Close Price | 986.20 | 933.38 | 663.08 | 305.75 | 111.20 | 134.59 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 14.82 | 15.54 | 1.72 | - | - | - |
Forward PE | 13.18 | 13.68 | 13.18 | 26.97 | 22.79 | 72.99 |
PS Ratio | 1.82 | 1.78 | 1.35 | 1.85 | 0.70 | 1.01 |
PB Ratio | 2.89 | 2.75 | 2.38 | 3.48 | 1.19 | 1.31 |
P/TBV Ratio | 5.31 | 5.04 | 4.29 | 6.75 | 2.28 | 2.49 |
P/FCF Ratio | 31.94 | 30.37 | 14.12 | 12.37 | - | - |
P/OCF Ratio | 12.94 | 12.30 | 9.01 | 10.29 | 58.23 | - |
PEG Ratio | - | 4.38 | 4.38 | 4.38 | 4.38 | 11.41 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 2.14 | 2.12 | 1.79 | 2.47 | 1.50 | 1.79 |
EV/EBITDA Ratio | 12.59 | 12.65 | 10.63 | 17.91 | 16.30 | - |
EV/EBIT Ratio | 16.36 | 15.86 | 13.41 | 26.66 | 38.52 | - |
EV/FCF Ratio | 37.55 | 36.22 | 18.71 | 16.50 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.56 | 0.56 | 0.73 | 1.22 | 1.39 | 1.27 |
Debt / EBITDA Ratio | 2.07 | 2.08 | 2.37 | 4.39 | 8.10 | - |
Debt / FCF Ratio | - | 6.18 | 4.30 | 4.32 | - | - |
Net Debt / Equity Ratio | 0.49 | 0.49 | 0.65 | 1.08 | 1.23 | 1.19 |
Net Debt / EBITDA Ratio | 1.89 | 1.91 | 2.19 | 4.15 | 7.84 | -57.45 |
Net Debt / FCF Ratio | - | 5.46 | 3.85 | 3.82 | -52.82 | -7.08 |
Asset Turnover | - | 0.75 | 0.77 | 0.62 | 0.54 | 0.44 |
Inventory Turnover | - | 1.47 | 1.77 | 1.68 | 1.52 | 1.36 |
Quick Ratio | - | 0.60 | 0.62 | 0.55 | 0.59 | 0.58 |
Current Ratio | - | 1.25 | 1.20 | 1.03 | 1.09 | 0.99 |
Return on Equity (ROE) | - | 20.03% | 17.58% | -6.78% | -10.13% | -18.25% |
Return on Assets (ROA) | - | 6.26% | 6.41% | 3.62% | 1.32% | -2.12% |
Return on Invested Capital (ROIC) | 11.82% | 12.45% | 11.96% | 7.90% | 2.86% | -4.69% |
Return on Capital Employed (ROCE) | - | 16.10% | 17.60% | 12.20% | 3.90% | -6.70% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 6.75% | 6.44% | 58.26% | -0.98% | -7.84% | -14.79% |
FCF Yield | 3.13% | 3.29% | 7.08% | 8.08% | -1.95% | -12.89% |
Dividend Yield | 0.52% | 0.54% | 0.60% | 0.82% | 1.35% | - |
Payout Ratio | - | 6.63% | 0.64% | - | - | - |
Buyback Yield / Dilution | -0.13% | -0.17% | -1.12% | -1.02% | -0.37% | -0.04% |
Total Shareholder Return | 0.40% | 0.37% | -0.52% | -0.20% | 0.98% | -0.04% |